8. เอกสารอ้างอิง
1. Dinesh DC, Chalupska D, Silhan J, Koutna E, Nencka R, et al. (2020) Structural basis of
RNA recognition by the SARS-CoV-2 nucleocapsid phosphoprotein. PLOS Pathogens
16(12): e1009100. https://doi.org/10.1371/journal.ppat.1009100
2. World Health Organization. Coronavirus. WHO Coronavirus disease (COVID-19).
AccessedApril20,2020. https://www.who.int/thailand/health-topics/coronavirus
3. Bliddal S, Banasik K, Pedersen OB, Nissen J, Cantwell L, Schwinn M, et al. Acute and
persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Sci Rep.
2021;11(1):13153.
4. Abdelrahman MM, Abd-Elrahman NM, Bakheet TM. Persistence of symptoms after
improvement of acute COVID19 infection, a longitudinal study. J Med
Virol.2021;93:5942-6.
5. Barker-Davies RM, O'Sullivan O, Senaratne KPP, Baker P, Cranley M, Dharm-Datta S, et
al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br
J Sports Med. 2020;54:949-59.
6. Tanking, C. (2020). How COVID-19 affects cancer and cardiovascular disease. The
Journal of Chulabhorn Royal Academy, 2(3), 18–26. Retrieved from https://he02.tci-
thaijo.org/index.php/jcra/article/view/241371
7. Paterson I, Ramanathan K, Aurora R, Bewick D, Chow CM, Clarke B et al. Long COVID-
A Primer for Cardiovascular Health Professionals, on Behalf of the CCS RapidResponse
Team. Can J Cardiol. 2021;37(8):1260-2.
8. ราชวิทยาลัยแพทย์เวชศาสตร์ฟื้นฟูแห่งประเทศไทย. การดูแลรักษาผู้ป่วยโควิด-19 หลังรักษาหาย
(POST COVID SYNDROME) หรือภาวะ LONG COVID สาหรับแพทย์และบุคลากรสาธารณสุข
สืบค้นจาก https://covid19.dms.go.th/Content/Select_Landding_page?contentId=157
9. Pirker-Kees A, Platho-Elwischger K, Hafner S, Redlich K, Baumgartner C. Hyposmia Is
Associated with Reduced Cognitive Function in COVID-19: First Preliminary
Results.Dementia and geriatric cognitive disorders. 2021;50(1):68-73.
10. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio
A,et al. More than 50 long-term effects of COVID-19: a systematic review and meta-
analysis.Scientific reports. 2021;11(1):16144.
11. Abrantes TF, Artounian KA, Falsey R, Simao JCL, Vano-Galvan S, Ferreira SB, et al.
Time of onset and duration of post-COVID-19 acute telogen effluvium. J Am Acad
Dermatol. 2021;85(4):975-6.
12. Moreno-Arrones OM, Lobato-Berezo A, Gomez-Zubiaur A, Arias-Santiago S, Saceda-
Corralo D, Bernardez-Guerra C, et al. SARS-CoV-2-induced telogen effluvium: a
multicentric study. J Eur Acad Dermatol Venereol. 2021;35(3):e181-e3.
13. Trueb RM. Systematic approach to hair loss in women. J Dtsch Dermatol Ges.
2010;8(4):284-97, -98.
14. Whiting DA. Chronic telogen effluvium: increased scalp hair shedding in middle-aged
women. J Am Acad Dermatol. 1996;35(6):899-906.
9. 15. Cheung EJ, Sink JR, English Iii JC. Vitamin and Mineral Deficiencies in Patients With
Telogen Effluvium: A Retrospective Cross-Sectional Study. J Drugs Dermatol.
2016;15(10):1235-7.
16. Chien Yin GO, Siong-See JL, Wang ECE. Telogen Effluvium - a review of the science
and current obstacles. J Dermatol Sci. 2021;101(3):156-63.
17. Malkud S. Telogen Effluvium: A Review. J Clin Diagn Res. 2015;9(9):WE01-3.
18. Grover C, Khurana A. Telogen effluvium. Indian J Dermatol Venereol Leprol.
2013;79(5):591-603.
19. Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, et al.
Evidence- based (S3) guideline for the treatment of androgenetic alopecia in women
and in men. J Dtsch Dermatol Ges. 2011;9 Suppl 6:S1-57.
20. Mysore V, Parthasaradhi A, Kharkar RD, Ghoshal AK, Ganjoo A, Ravichandran G, et al.
Expert consensus on the management of Telogen Effluvium in India. Int J Trichology.
2019;11(3):107-12.